Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Melinta Therapeutics

Melinta Therapeutics?uq=UG6efJS6
2000 FOUNDED
PUBLIC STATUS
201-300 EMPLOYEES
MLNT STOCK SYMBOL
2 INVESTMENTS
$3.78 SHARE PRICE (As of Friday Closing)
Description

Developer of novel small-molecule antibiotics intended to focus on the treatment of resistant infections. The company's novel small-molecule antibiotics are used for resistant infections, acute bacterial skin infections, methicillin-resistant staph infections and gonorrhea, enabling patients avail novel antibiotics that are advanced and continuously enhanced in terms of quality.

Website
Formerly Known As
Rib-X Pharmaceuticals, Rib-X Designs
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 300 George Street
  • Suite 301
  • New Haven, CT 06511
  • United States

+1 (312) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Melinta Therapeutics’s full profile, request a free trial.

Melinta Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.73 - $17.25 $213M $3.80 -$20.90 436K 56M

Melinta Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 370,270 181,798 (85,282) 1,207,122
Revenue 54,995 33,864 0 0
EBITDA (72,153) (50,996) (69,059) (74,923)
Net Income (108,973) (58,916) (73,932) (78,676)
Total Assets 514,647 160,273 16,634 162,140
Total Debt 107,463 39,555 68,849 19,702
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Melinta Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Melinta Therapeutics‘s full profile, request access.

Request full access to PitchBook

Melinta Therapeutics Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 0000 05-Jan-2018 000000000000000000 00000 Drug Discovery 000000 00000000
Cempra Pharmaceuticals 03-Nov-2017 Merger/Acquisition Pharmaceuticals 0000 000000
To view this company’s complete investment and acquisition history, request access »

Melinta Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Melinta Therapeutics‘s full profile, request access.

Request full access to PitchBook

Melinta Therapeutics Executive Team (19)

Name Title Board
Seat
Contact
Info
Daniel Wechsler President, Board Member & Chief Executive Officer
Erin Duffy Ph.D Chief Scientific Officer & Executive Vice President
Rajesh Mistry Director, Investor Relations
Michael Kenston Chief Commercial Officer
Sue Cammarata MD Chief Medical Officer & Executive Vice President

8 Former Executives

You’re viewing 5 of 19 executives. Get the full list »

Melinta Therapeutics Board Members (20)

Name Representing Role Since Contact
Info
Cecilia Gonzalo Vatera Healthcare Partners Board Member 000 0000
Christopher Kiritsy Self Board Member 000 0000
Erik Akhund Self Board Member 000 0000
John Sununu Self Board Member 000 0000
Kevin Ferro Vatera Healthcare Partners Board Member 000 0000

11 Former Board Members

You’re viewing 5 of 20 board members. Get the full list »